ATAI Life Sciences N.V. (now Atai Beckley N.V.) reported its financial results for the third quarter of 2025, revealing a total revenue of $749,000, a significant increase from $40,000 in the same period last year. The revenue for the nine months ending September 30, 2025, reached $3.0 million, compared to $313,000 for the same period in 2024. The increase in revenue was primarily driven by $2.8 million in research and development services, a new revenue stream for the company, while license revenue decreased to $202,000 from $313,000 year-over-year due to the termination of the Otsuka Agreement.
Operating expenses for the third quarter totaled $29.2 million, up from $22.6 million in the prior year, reflecting a 29% increase. This rise was attributed to higher research and development costs, which increased by 19% to $14.7 million, and general and administrative expenses, which rose by 41% to $14.5 million. The net loss for the quarter was $61.1 million, compared to a loss of $26.3 million in the same quarter of 2024, marking a 132% increase in losses. The loss attributable to Atai Beckley N.V. stockholders was $61.1 million, or $0.28 per share, compared to a loss of $0.16 per share in the previous year.
The company has undergone significant strategic developments, including the completion of its acquisition of Beckley Psytech on November 5, 2025, which is expected to enhance its product pipeline and market position. The acquisition was part of a broader strategy to expand its offerings in the mental health treatment space, particularly through psychedelic-based therapies. Additionally, the company has restructured its operations, resulting in a workforce reduction of approximately 25% to streamline costs and extend its cash runway.
As of September 30, 2025, Atai Beckley reported cash and cash equivalents of $30.4 million and short-term securities valued at $84.2 million, up from $17.5 million and $44.8 million, respectively, at the end of 2024. The accumulated deficit increased to $815.4 million, reflecting ongoing investments in research and development. The company anticipates that its existing cash and securities will be sufficient to fund operations for at least the next 12 months, although it expects to continue incurring significant losses until it can commercialize its product candidates.
Looking ahead, Atai Beckley aims to advance its clinical programs, including BPL-003 for treatment-resistant depression and VLS-01 for buccal film DMT, with Phase 3 trials expected to begin in mid-2026. The company is also focused on optimizing its product pipeline and exploring additional strategic partnerships to enhance its market presence in the mental health sector.
About ATAI Life Sciences N.V.
ATAI Life Sciences N.V. is a clinical-stage biopharmaceutical company focused on developing innovative mental health treatments, primarily through psychedelic and non-psychedelic drug candidates. Its diversified pipeline targets disorders such as treatment-resistant depression, social anxiety, and cognitive impairment associated with schizophrenia. ATAI advances proprietary compounds and strategic investments, leveraging novel drug delivery technologies and intellectual property to address significant unmet medical needs in global mental health markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.